Given the importance of SHIP1 in regulating immune cell function and PI3K signaling, therapeutic targeting of SHIP1 has been tested in treatments of leukemia, lymphoma, and inflammatory and autoimmune disease (14). Here, INPP5D is linked to leukemia.